|
Mar 28
|
Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer
|
|
Mar 27
|
Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner
|
|
Mar 26
|
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
|
|
Mar 26
|
3 Growth Stocks to Buy at 52-Week Lows in March
|
|
Mar 25
|
How Much Upside is Left in Exact Sciences (EXAS)? Wall Street Analysts Think 53.83%
|
|
Mar 25
|
Here's How Much You'd Have If You Invested $1000 in Exact Sciences a Decade Ago
|
|
Mar 22
|
Exact Sciences (EXAS) Up 4.2% Since Last Earnings Report: Can It Continue?
|
|
Mar 21
|
Exact Sciences Corporation (NASDAQ:EXAS) is largely controlled by institutional shareholders who own 89% of the company
|
|
Mar 18
|
Exact Sciences' (EXAS) BLUE-C Study Results Published in NEJM
|
|
Mar 18
|
Guardant posts data for colon cancer blood test amid push from rivals
|
|
Mar 13
|
Cathie Wood Darling Exact Sciences Rises On Highly Anticipated Colon Cancer News
|
|
Mar 13
|
The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Study
|
|
Mar 11
|
The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
|
|
Mar 11
|
2 Beaten-Down Cathie Wood Stocks With Massive Potential
|
|
Mar 8
|
Can Exact Sciences (EXAS) Climb 55.43% to Reach the Level Wall Street Analysts Expect?
|
|
Mar 8
|
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
|
|
Mar 7
|
Exact Sciences and Basketball Great Jamal Mashburn Encourage Americans 45+ to Have a Game Plan Against Colon Cancer
|
|
Mar 5
|
Exact Sciences Corp (EXAS) Director Daniel Levangie Sells 5,000 Shares
|
|
Mar 4
|
The Top 3 Healthcare Stocks to Buy on Weakness in 2024
|
|
Mar 4
|
7 Stable Stocks to Buy for 100% Returns by 2025
|